TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA

Autor:	E. A. Baryakh
Jazyk:	ruština
Rok vydání:	2017
Předmět:	hodgkin lymphoma relapse refractory disease cd30 autologous hematopoietic cell transplantation brentuximab vedotin Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	Онкогематология, Vol 12, Iss 2, Pp 8-13 (2017)
Druh dokumentu:	article
ISSN:	1818-8346 2413-4023
DOI:	10.17650/1818-8346-2017-12-2-8-13
Popis:	Hodgkin lymphoma (HL) represents one of the great success stories in hematology going from a uniformly fatal disease; to one that is curable in the vast majority of cases. Despite this success; approximately 5–10 % HL patients are refractory to initial treatment and 10–30 % of patients will relapse after achieving an initial complete remission. The standard treatment is second-line therapy followed by autologous hematopoietic stem cell transplantation (autoHSCT); which cures an additional 50 % of patients. Brentuximab Vedotin; “antibody-drug conjugate”; dramatically changed the possibilities of therapy for relapses/refractory HL. The article presents a review of the literature on the treatment of relapses/refractory HL.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/fbcd4745866f4976927ca50449739905 Zobrazit plný text záznamu View record in DOAJ